ファーマコビジランス・医薬品安全性ソフトウェア市場：製品、臨床試験、流通、エンドユーザー別-世界予測2024～2030年

ファーマコビジランス・医薬品安全性ソフトウェア市場規模は2023年に5億5,210万米ドルと推定され、2024年には6億2,931万米ドルに達し、CAGR 14.55％で2030年には14億2,924万米ドルに達すると予測されています。

ファーマコビジランス・医薬品安全性ソフトウェアには、副作用やその他の薬剤関連の問題を監視、評価、理解、予防するために設計されたさまざまなデジタルプラットフォームが含まれます。これらのソフトウェアソリューションは、製薬会社やバイオテクノロジー企業、医薬品開発業務受託機関（CRO）、規制当局、その他医薬品開発プロセスや市販後調査に不可欠な企業によって採用されています。その主要目的は、世界の規制基準へのコンプライアンスを確保し、報告プロセスを合理化し、患者の安全性の結果を改善することです。新薬の開発に伴い拡大する製薬業界では、ファーマコビジランス・医薬品安全性ソフトウェアの必要性が高まっています。データ量の増加に伴う効率的なデータ管理システムの必要性に伴うデジタル技術の採用拡大が、市場成長の原動力となっています。ファーマコビジランスと医薬品安全性ソフトウェアに関連するデータセキュリティとプライバシーの問題が市場成長の妨げとなっています。生データをより良いリスク管理のための実用的な洞察に変換するための高度な分析機能への投資の増加や、効率的なワークフロー管理と非技術系ユーザーでも使いやすい直感的なUI/UXデザインの作成が、市場成長の機会を生み出すと期待されています。

製品：ファーマコビジランス規制の遵守を確実にするため、医薬品安全性監査ソフトウェアの利用が拡大

有害事象報告ソフトウェアは、医薬品の使用に関連する有害事象（AE）の体系的な記録と管理に不可欠です。このソフトウェアにより、製薬会社、規制当局、医療プロバイダーは、多くの法域で規制要件となっている副作用の文書化と報告を行うことができます。これらのシステムには、潜在的な有害事象にフラグを立てたり、報告プロセスを自動化したり、FDAやEMAが定めるような世界スタンダードへのコンプライアンスを確保したりする機能が備わっていることがよくあります。医薬品安全性監査ソフトウェアは、ファーマコビジランス規制へのコンプライアンスを確保するように設計されています。監査ライフサイクルを追跡することで、この種のソフトウェアはファーマコビジランス監査の実施、報告、フォローアップをサポートし、企業がコンプライアンスを維持し、規制当局の査察に備えることを容易にします。完全に統合されたファーマコビジランス・ソフトウェア・システムは、AEデータの取得から規制当局への提出まで、エンドツーエンドの医薬品安全性ソリューションを記載しています。これらのシステムには、症例処理、シグナル検出、リスク管理、レポート作成の機能が1つのプラットフォームに含まれていることが多く、複数のシステムを使用する必要がありません。ファーマコビジランスにおける問題追跡ソフトウェアは、安全性問題の効率的な管理と解決を支援します。これらのシステムはメーカーにとって重要であり、AE症例調査、根本原因分析、是正措置計画に関する複雑なワークフローをナビゲートすることができます。

エンドユーザー：臨床試験データの取り扱いと高度なレポーティング機能を提供する契約研究機関におけるファーマコビジランス・医薬品安全性ソフトウェアの可能性

ビジネスプロセスアウトソーシング（BPO）企業は、ファーマコビジランス活動を含むサードパーティサービスを製薬企業やバイオテクノロジー企業に提供しています。これらの企業は、顧客の多様なデータを効率的に管理し、さまざまな規制基準に準拠するために、堅牢な医薬品安全性ソフトウェアを必要としています。契約研究機関は、臨床試験管理やファーマコビジランスを含む研究サービスを製薬業界に契約ベースで提供しています。製薬・バイオテクノロジー企業は医薬品開発の最前線にいるため、製品ライフサイクル全体を通じて医薬品の安全性とファーマコビジランスに本質的に責任があります。ファーマコビジランスサービス・プロバイダーは、他の医療事業体向けの医薬品安全性モニタリングとレポートサービスを専門としており、一般的に、大量のデータトランザクションやマルチクライアント環境に適応した専門的なファーマコビジランス・ソフトウェアを必要とします。

地域洞察

北米と南米にまたがるこの地域では、厳しい規制と洗練された医療インフラがファーマコビジランス・医薬品安全性ソフトウェアに対する大きな需要を牽引しています。南北アメリカは、技術の導入、研究開発への投資、医薬品の安全性を確保するための規制の実施という点でリードしています。カナダは、強固な医療システムとファーマコビジランスへの注力の高まりでこれに続く。欧州連合（EU）は、EMA（欧州医薬品庁）を通じて規制を統一しており、ファーマコビジランス（PV）・医薬品安全性ソフトウェアの成長市場となっています。EU諸国では、EMAが義務付ける副作用（ADR）報告、リスク管理計画要件、ファーマコビジランス監査戦略を遵守するため、PVソフトウェアソリューションの採用が増加しています。中東・アフリカ地域では、医療水準の向上や、医薬品をより効果的に規制するための政府の取り組みにより、ファーマコビジランスの成長率が高まっている国もあり、その導入レベルはさまざまです。アジア太平洋は、中国、インド、日本などの主要経済国で構成され、PVソフトウェアソリューションの主要市場として急速に台頭しています。医療支出の増加、医薬品の安全性に関する意識の高まり、製薬部門の成長が、この地域のファーマコビジランスソフトウェア市場の拡大に貢献しています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは、ファーマコビジランス・医薬品安全性ソフトウェア市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ファーマコビジランス・医薬品安全性ソフトウェア市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.ファーマコビジランス・医薬品安全性ソフトウェア市場の市場規模と予測は？

2.ファーマコビジランス・医薬品安全性ソフトウェア市場の予測期間中に投資を検討すべき製品、用途は何か？

3.ファーマコビジランス・医薬品安全性ソフトウェア市場の技術動向と規制枠組みは？

4.ファーマコビジランス・医薬品安全性ソフトウェア市場における主要ベンダーの市場シェアは？

5.ファーマコビジランス・医薬品安全性ソフトウェア市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ADRと薬剤毒性の発生率の上昇
    • 集計レポートや論文のための医療文献の検討に費やす時間を削減する必要性が高まっている
    • 厳しく規制された医薬品安全性監視セグメント
  • 抑制要因
    • ファーマコビジランス・医薬品安全性ソフトウェアの高価な展開
  • 機会
    • 医療企業による研究開発（R&D）への投資の増加
    • ファーマコビジランス・医薬品安全性ソフトウェアにおけるAIと機械学習モデルの統合
  • 課題
    • 新興諸国における医薬品有害反応（ADR）に関する認識、トレーニング、報告不足
• 市場セグメンテーション分析
  • 製品：医薬品安全性監視規制への準拠を確保するための医薬品安全性監査ソフトウェアの使用が増加
  • エンドユーザー：臨床試験データを処理し、高度なレポート機能を提供する契約研究機関におけるファーマコビジランス・医薬品安全性ソフトウェアの可能性
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 ファーマコビジランス・医薬品安全性ソフトウェア市場：製品別

• イントロダクション
• 有害事象報告ソフトウェア
• 医薬品安全性監査ソフトウェア
• 完全に統合されたソフトウェア
• 問題追跡ソフトウェア

第7章 ファーマコビジランス・医薬品安全性ソフトウェア市場：臨床試験別

• イントロダクション
• フェーズI
• フェーズII
• フェーズIII
• フェーズIV
• 前臨床

第8章 ファーマコビジランス・医薬品安全性ソフトウェア市場：流通別

• イントロダクション
• クラウド
• オンプレミス

第9章 ファーマコビジランス・医薬品安全性ソフトウェア市場：エンドユーザー別

• イントロダクション
• ビジネスプロセスアウトソーシング企業
• 契約研究機関
• 製薬・バイオテクノロジー企業
• 医薬品安全性監視サービスプロバイダー

第10章 南北アメリカのファーマコビジランス・医薬品安全性ソフトウェア市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋のファーマコビジランス・医薬品安全性ソフトウェア市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのファーマコビジランス・医薬品安全性ソフトウェア市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET RESEARCH PROCESS
• FIGURE 2. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET DYNAMICS
• FIGURE 7. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ADVERSE EVENT REPORTING SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ADVERSE EVENT REPORTING SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DRUG SAFETY AUDITS SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DRUG SAFETY AUDITS SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY FULLY INTEGRATED SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY FULLY INTEGRATED SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ISSUE TRACKING SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ISSUE TRACKING SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE I, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE I, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE II, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE II, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE III, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE III, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE IV, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ON-CLOUD, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ON-CLOUD, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ON-PREMISE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY BUSINESS PROCESS OUTSOURCING FIRMS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY BUSINESS PROCESS OUTSOURCING FIRMS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHARMACOVIGILANCE SERVICE PROVIDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHARMACOVIGILANCE SERVICE PROVIDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 53. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 54. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 57. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 58. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 59. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 60. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 61. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 62. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 63. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 64. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 65. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 66. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 67. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 68. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 69. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 70. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 71. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 72. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 73. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 74. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 75. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 76. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 77. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 78. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 79. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 80. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 81. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 82. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 83. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 84. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 85. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 86. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 87. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 88. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 89. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 90. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 91. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 92. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 93. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 94. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 95. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 96. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 98. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 100. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 102. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 104. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 106. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 107. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 108. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 109. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 110. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 111. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 112. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 113. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 114. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 115. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 116. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 117. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 118. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 119. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 120. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 121. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 122. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 123. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 124. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 125. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 126. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 127. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 128. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 129. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 130. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 131. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 132. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 133. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 134. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 135. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 136. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 137. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 138. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 139. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 140. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 141. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 142. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 143. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 144. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 145. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 146. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 147. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 148. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 149. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 150. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 151. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 152. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 153. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 154. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 155. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 156. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 157. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 158. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 159. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 160. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 161. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 162. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 163. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 164. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 165. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 166. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 167. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 168. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 169. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 170. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 172. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 173. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 174. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 175. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 176. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 177. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 178. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 179. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 180. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 181. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 182. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 183. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 184. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 185. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 186. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 187. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 188. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 189. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 190. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 191. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 192. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 193. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 194. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 195. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 196. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 197. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 198. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 199. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 200. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 201. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 202. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 213. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 214. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 215. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 216. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 217. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 218. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 219. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 220. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 221. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 222. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 223. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 224. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 225. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 226. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 227. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 228. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 229. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 230. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 231. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 232. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 233. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 234. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 235. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 236. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 237. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 238. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 239. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 240. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 241. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 242. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 243. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 244. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 245. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 246. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 247. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 248. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 249. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 250. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 251. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 252. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 253. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 254. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 255. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 256. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 257. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 258. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 259. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 260. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 261. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 262. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 263. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 264. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 265. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 266. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 267. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 268. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 269. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 270. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 271. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 272. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 273. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 274. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 275. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 276. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 277. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 278. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 279. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2023 (USD MILLION)
• TABLE 280. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2024-2030 (USD MILLION)
• TABLE 281. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
• TABLE 282. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
• TABLE 283. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 284. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 285. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 286. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2024-20

[188 Pages Report] The Pharmacovigilance & Drug Safety Software Market size was estimated at USD 552.10 million in 2023 and expected to reach USD 629.31 million in 2024, at a CAGR 14.55% to reach USD 1,429.24 million by 2030.

The pharmacovigilance & drug safety software encompasses a range of digital platforms designed to monitor, assess, understand, and prevent adverse effects or other drug-related problems. These software solutions are employed by pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory agencies, and others integral to the drug development process and post-marketing surveillance. The primary aim is to ensure compliance with global regulatory standards, streamline reporting processes, and improve patient safety outcomes. The expanding pharmaceutical industry with the rising development of novel drugs is raising the need for pharmacovigilance & drug safety software. The growing adoption of digital technologies with the need for efficient data management systems in the face of growing data volumes is driving the market growth. Data security and privacy issues associated with pharmacovigilance and drug safety software hamper the market growth. Rising investments in advanced analytics capabilities to transform raw data into actionable insights for better risk management and creating intuitive UI/UX designs that enable efficient workflow management and ease of use, even for non-technical users, are expected to create opportunities for market growth.

Product: Growing usage of drug safety audit software to ensure compliance with pharmacovigilance regulations

Adverse event reporting software is essential for the systematic recording and managing of adverse events (AEs) related to drug usage. This software enables pharmaceutical companies, regulatory agencies, and healthcare providers to document and report adverse reactions, which is a regulatory requirement in many jurisdictions. These systems often come with features for flagging potential adverse events, automating the reporting process, and ensuring compliance with global standards such as those set by the FDA and EMA. Drug safety audit software is designed to ensure compliance with pharmacovigilance regulations. By tracking the audit lifecycle, this type of software supports the conduct, reporting, and follow-up of pharmacovigilance audits, thus making it easier for companies to remain compliant and prepare for regulatory inspections. Fully integrated pharmacovigilance software systems offer end-to-end drug safety solutions, from AE data capture to regulatory submission. These systems often include features for case processing, signal detection, risk management, and reporting in one platform, eliminating the need for multiple systems. Issue tracking software in pharmacovigilance helps manage and resolve safety issues efficiently. These systems are critical for manufacturers, enabling them to navigate complex workflows around AE case investigation, root cause analysis, and corrective action planning.

End User: Potential of pharmacovigilance & drug safety software among contract research organizations for handling clinical trial data and offering advanced reporting capabilities

Business process outsourcing (BPO) firms offer third-party services to pharmaceutical and biotechnology companies, including pharmacovigilance activities. These firms require robust drug safety software to manage their clients' diverse data efficiently and comply with various regulatory standards. Contract research organizations provide research services to the pharmaceutical industry on a contractual basis, including clinical trial management and pharmacovigilance. Pharmaceutical & biotechnology companies are at the forefront of drug development and, thus, inherently responsible for drug safety and pharmacovigilance throughout the product lifecycle. Pharmacovigilance service providers specialize in drug safety monitoring and report services for other healthcare entities and typically require specialized pharmacovigilance software adapted to high-volume data transactions and multi-client environments.

Regional Insights

Encompassing both North and South America, the region demonstrates a significant demand for pharmacovigilance & drug safety software largely driven by stringent regulations and a sophisticated healthcare infrastructure. The Americas leads in terms of adoption of technology, investment in R&D, and implementation of regulations to ensure drug safety. Canada follows with a robust healthcare system and a growing focus on pharmacovigilance. The European Union, with its harmonized regulations through the EMA (European Medicines Agency), presents a growing market for pharmacovigilance (PV) & drug safety software. EU countries have seen increasing adoption of PV software solutions to comply with adverse drug reaction (ADR) reporting, risk management plan requirements, and pharmacovigilance audit strategies as mandated by the EMA. The MEA region shows varied levels of adoption, with certain countries exhibiting increased growth in pharmacovigilance due to rising healthcare standards and government initiatives to regulate drugs more effectively. Comprising major economies such as China, India, and Japan, the Asia Pacific region is rapidly emerging as a key market for PV software solutions with the rising healthcare spending, increasing awareness about drug safety, and growing pharmaceutical sectors contributing to the expansion of the pharmacovigilance software market in this region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmacovigilance & Drug Safety Software Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmacovigilance & Drug Safety Software Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmacovigilance & Drug Safety Software Market, highlighting leading vendors and their innovative profiles. These include 4C Pharma Solutions, AB Cube S.A.S., Accenture PLC, Anju Software, Inc., ArisGlobal LLC, Certara, Inc., Clarivate, Clinevo Technologies Private Limited, Cloudbyz, Inc., Cognizant Technology Solutions Corporation, Ennov SAS, Ergomed PLC, Extedo GmbH, Freyr Software Services Pvt. Ltd., Indegene Inc., Infosys Limited, IQVIA Inc., NUVO Consultancy, Oracle Corporation, PureSoftware Limited, Sarjen Systems Private Limited, Sparta Systems, Inc., Tepsivo Oy, TriNetX, LLC, United BioSource LLC, and Wipro Limited.

Market Segmentation & Coverage

This research report categorizes the Pharmacovigilance & Drug Safety Software Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Adverse Event Reporting Software
  • Drug Safety Audits Software
  • Fully Integrated Software
  • Issue Tracking Software

• Clinical Trial
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Pre-clinical

• Distribution
  • On-Cloud
  • On-Premise

• End User
  • Business Process Outsourcing Firms
  • Contract Research Organizations
  • Pharma & Biotech Companies
  • Pharmacovigilance Service Providers

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pharmacovigilance & Drug Safety Software Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmacovigilance & Drug Safety Software Market?

3. What are the technology trends and regulatory frameworks in the Pharmacovigilance & Drug Safety Software Market?

4. What is the market share of the leading vendors in the Pharmacovigilance & Drug Safety Software Market?

5. Which modes and strategic moves are suitable for entering the Pharmacovigilance & Drug Safety Software Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Incidence of ADR and Drug Toxicity
    • 5.1.1.2. Increasing Need to Reduce Time Spent Reviewing Medical Literature for Aggregate Reports and Articles
    • 5.1.1.3. Highly Regulated Pharmacovigilance Space
  • 5.1.2. Restraints
    • 5.1.2.1. Expensive Deployment of Pharmacovigilance & Drug Safety Software
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Investment in Research and Development (R&D) by Healthcare Companies
    • 5.1.3.2. Integration of AI and Machine Learning Models in Pharmacovigilance & Drug Safety Software
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of Awareness, Training, and Underreporting of Adverse Drug Reactions (ADRs) in Developing Countries
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Growing usage of drug safety audit software to ensure compliance with pharmacovigilance regulations
  • 5.2.2. End User: Potential of pharmacovigilance & drug safety software among contract research organizations for handling clinical trial data and offering advanced reporting capabilities
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Pharmacovigilance & Drug Safety Software Market, by Product

• 6.1. Introduction
• 6.2. Adverse Event Reporting Software
• 6.3. Drug Safety Audits Software
• 6.4. Fully Integrated Software
• 6.5. Issue Tracking Software

7. Pharmacovigilance & Drug Safety Software Market, by Clinical Trial

• 7.1. Introduction
• 7.2. Phase I
• 7.3. Phase II
• 7.4. Phase III
• 7.5. Phase IV
• 7.6. Pre-clinical

8. Pharmacovigilance & Drug Safety Software Market, by Distribution

• 8.1. Introduction
• 8.2. On-Cloud
• 8.3. On-Premise

9. Pharmacovigilance & Drug Safety Software Market, by End User

• 9.1. Introduction
• 9.2. Business Process Outsourcing Firms
• 9.3. Contract Research Organizations
• 9.4. Pharma & Biotech Companies
• 9.5. Pharmacovigilance Service Providers

10. Americas Pharmacovigilance & Drug Safety Software Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Pharmacovigilance & Drug Safety Software Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacovigilance & Drug Safety Software Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. RxLogix Corporation Announces Landmark Partnership with the European Medicines Agency (EMA) for a Cutting-Edge Safety Solution
  • 13.3.2. Launch by JNPMEDI of 'Maven Safety,' a drug safety management solution

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio